28 June 2018 - Neurolixis Appoints Dr. Ronan Depoortère, PhD, as Director of Pharmacology

Neurolixis Inc. offers a warm welcome to Ronan Depoortere, PhD, as Director of Pharmacoogy.
Dr. Depoortere has gained extensive experience of neuropharmacology in several large and medium-sized pharmaceutical companies where he managed in vivo behavioral studies on CNS drug candidates. His expertise will be valuable as Neurolixis moves forward with development of its drug pipeline targeting Parkinson's disease and Rett syndrome and in characterizing development candidates from the drug discovery program.

See more information concerning Neurolixis' management team here.

24 February 2018 - Patent published on novel serotonin 5-HT1A receptor agonists

Neurolixis announced the publication of a new patent on a series of serotonin 5-HT1A receptor agonists. The novel chemical entities (NCEs) are structural analogues of Neurolixis' lead compounds, NLX-112 and NLX-101 which are in clinical development for treatment of dyskinesia in Parkinson's disease and Rett syndrome, respectively. Patent WO/2017/220799 (priority date 24 June 2016) has co-inventors from Neurolixis and from Jagiellonian University, Krakow, as part of a continuing and fruitful drug discovery collaboration.

See the text of the patent on the World Intellectual Property website: WO/2017/220799